Patient-specific antiplatelet therapy

Journal of Thrombosis and Thrombolysis

Volumn 17, Issue 1, 2004, Pages 63-77

  Conde, Ian D ^a   Kleiman, Neal S ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Abciximab; Aspirin; Integrilin; Patient; Thienopyridines; Tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ROFECOXIB; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANTICOAGULANT THERAPY; APLASTIC ANEMIA; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG USE; DYSPEPSIA; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEARTBURN; HEMATURIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; NAUSEA; NEUTROPENIA; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UPPER GASTROINTESTINAL BLEEDING; VOMITING;

HUMANS; PATIENT CARE PLANNING; PLATELET AGGREGATION INHIBITORS; VASCULAR DISEASES;

EID: 4143109161     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:THRO.0000036030.74243.49     Document Type: Review

References (85)

1. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336(12):847-860.
2. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994 330(18):1287-1294.
3. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975;72(8):2994-2998.
4. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978;61(2):314-319.
5. Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR. Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release. Blood 1993;82(2):505-512.
6. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2(8607):349-360.
7. Lewis HD, Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study N Engl J Med 1983;309(7):396-403.
8. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308(6921):81-106.
9. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001;357(9250):89-95.
10. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984 ;311(19):1206-1211.
11. Dabaghi SF, Kamat SG, Payne J, et al. Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. Am J Cardiol 1994;74(7):720-723.
12. De Caterina R, Giannessi D, Bernini W et al. Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. Am J Cardiol 1985;55(5):589-590.
13. Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991;325(16):1137-1141.
14. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials. Br J Clin Pharmacol 1993;35(3):219-226.
15. Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999;353(9171):2179-2184.
16. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86.
17. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically Can J Cardiol 1995;11(3):221-227.
18. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994 25(12):2331-2336.
19. Grotemeyer KR, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71(5):397-403.
20. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88(3):230-235.
21. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105(14):1650-1655.
22. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: A review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002;88(5):711-715.
23. Michelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet GPIIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000;101(9):1013-1018.
24. Rao GH, Johnson GG, Reddy KR, White JG. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 1983;3(4):383-388.
25. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxy-genase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001 ;345(25):1809-1817.
26. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: An observational cohort study. Lancet 2002;359(9301):118-123.
27. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361(9357):573-574.
28. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Strom B. Lower myocardial infarction risk amongst current users of non-aspirin non-steroidal anti-inflammatory medications. J Am Coll Cardiol 39. 2002. Abstract.
29. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78(3):1003-1007.
30. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348(9038):1329-1339.
31. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494-502.
32. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials. BMJ 2002;325(7365):619.
33. Mene P, Pugliese F, Patrono C. The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease. Semin Nephrol 1995;15(3):244-252.
34. Hansen HP, Gaede PH, Jensen BR, Parving HH. Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria. Diabetes Care 2000;23(12):1742-1745.
35. D'Agati V. Does aspirin cause acute or chronic renal failure in experimental animals and in humans? Am J Kidney Dis 1996;28(1 Suppl 1):S24-S29.
36. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339(4):229-234.
37. Solet DJ, Zacharski LR, Plehn JF. The role of adenosine 5′-diphosphate receptor blockade in patients with cardiovascular disease. Am J Med 2001;111(1):45-53.
38. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001;86(1):222-232.
39. Helft G, Osende JI, Worthley SG, et al. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol 2000;20(10):2316-2321.
40. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001;85(1):92-93.
41. Steinhubl SR, Berger PB, Mann JT, III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288(19):2411-2420.
42. Ronan Curtin, Dermot Fox, Desmond Fitzgerald. Clopidogrel and Ticlopidine. In: Alan D.Michelson, ed. Platelets. San Diego, CA: Academic Press, 2002:787-801.
43. Berger PB. Clopidogrel instead of ticlopidine after coronary stent placement: Is the switch justified? Am Heart J 2000;140(3):354-358.
44. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery Circulation 2001;103(3):363-368.
45. Lubbe DF, Berger PB. The thienopyridines. J Interv Cardiol 2002 15(1):85-93.
46. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358(9281):527-533.
47. Hongo R, Ley J, Yee R. Impact of preoperative clopidogrel in coronary artery bypass grafting. Circulation 102(II). 2000. Abstract.
48. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342(24):1773-1777.
49. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 2003;107(1):32-37.
50. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90(6):625-628.
51. Swarup V, Oh C, Richard EN. Risk of post-operative hemorrhage associated with ticlopidine or clopidogrel use prior to coronary artetry bypass grafting. Circulation 2000; 102(II), 648A. Abstract.
52. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002;40(2):231-237.
53. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92(9):2373-2380.
54. Coller BS. Anti-GPIIb/IIIa drugs: Current strategies and future directions. Thromb Haemost 2001;86(1):427-443.
55. Kohl DW, Slavik KJ, Kamath G, Lehr JM, McDonald MJ, Rubio F. High-dose abciximab during coronary angioplasty in a patient with essential thrombocytosis. J Invasive Cardiol 1998;10(3):173-176.
56. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade. Circulation 1998;97(17): 1680-1688.
57. Scarborough RM, Naughton MA, Teng W, et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993;268(2):1066-1073.
58. Ramtin Agah, Edward F.Plow, Eric J.Topol. GPIIb-IIIa Antagonists. In: Alan D.Michelson, ed. Platelets. San Diego, CA: Academic Press, 2002:769-785.
59. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999;341(5):319-327.
60. O'Shea JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: A randomized controlled trial. JAMA 2001 285(19):2468-2473.
61. Moliterno DJ, Yakubov SJ, DiBattiste PM, et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: The TARGET follow-up study. Lancet 2002;360(9330):355-360.
62. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002;359(9302):189-198.
63. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999;354(9192):1757-1762.
64. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999;340(21):1623-1629.
65. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344(25):1879-1887.
66. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial. Lancet 2001 ;357(9272):1915-1924.
67. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997;349(9063):1429-1435.
68. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study Circulation 2001 103(21):2572-2578.
69. Cura FA, Bhatt DL, Lincoff AM, et al. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. Circulation 2000;102(1):28-34.
70. Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: A pooled analysis of five randomized clinical trials. Circulation 2002;106(24):3063-3067.
71. Al Suwaidi J, Reddan DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002;106(8):974-980.
72. Antiplatelet and Antithrombotic Prescribing Guide, 1st ed. Montvale, NJ: Medical Economics Publisher, 2000.
73. Januzzi JL, Jr., Snapinn SM, DiBattiste PM, Jang IK, Theroux P. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation 2002 105(20):2361-2366.
74. Reddan DN, O'Shea JC, Sarembock IJ, et al. Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). Am J Cardiol 2003;91(1):17-21.
75. Frilling B, Zahn R, Fraiture B, et al. Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol 2002;89(4):450-452.
76. Jeremias A, Bhatt DL, Chew DP, et al. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency Am J Cardiol 2002;89(10):1209-1211.
77. Kornowski R, Lansky AJ. Current perspectives on interventional treatment strategies in diabetic patients with coronary artery disease. Catheter Cardiovasc Interv 2000;50(2):245-254.
78. Diethelm Tschoepe, Barbara Menart-Houtermans. Diabetes Mellitus. In: Alan D.Michelson, ed. Platelets. San Diego, CA: Academic Press, 2002:435-445.
79. Marso SP, Lincoff AM, Ellis SG, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic sub-study. Circulation 1999;100(25):2477-2484.
80. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35(4):922-928.
81. Iakovou I, Dangas G, Mehran R, et al. Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors. Am J Cardiol 2002;89(8):976-979.
82. Fernandes LS, Tcheng JE, O'Shea JC, et al. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study. J Am Coll Cardiol 2002;40(6):1085-1091.
83. Blankenship JC. Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors. Am Heart J 1999;138(4 Pt 2):287-296.
84. Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 1998;32(2):311-319.
85. Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab readministration: Results of the ReoPro Readministration Registry. Circulation 2001 104(8):870-875.